Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown
Published: May 13, 2025
Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly used for the management of people living with type 2 diabetes mellitus (T2DM) and/or obesity. Numerous concordant animal and human studies suggest that GLP‐1RAs could reduce risk addiction, especially alcohol use disorders (AUD). This comprehensive review aims at summarising known effects on AUD. An extensive literature search detected clinical (either observational or controlled) investigated prevalence severity AUD in obese/T2DM patients treated compared a control group. In seven cohort (12 paired data comparisons), was reduced by 35% (hazard ratio 0.65; 95% confidence interval 0.56–0.74) GLP‐1RA therapy when to no‐GLP‐1 therapy. The protection concerned both incidence recurrence These positive findings confirm preclinical rodents monkeys. Some genetic, experimental functional neuroimaging also supported potential role GLP‐1 system alcohol‐related reward process. Only two randomised controlled trials available yet inconclusive results, but several ongoing protective effect semaglutide Different neuronal psychological mechanisms involving pathways proposed explain favourable reported GLP‐1RAs. conclusion, from showed significantly consumption habits However, further required before considering any indication prevention
Language: Английский